Arming Vδ2 T Cells With Chimeric Antigen Receptors to Combat Cancer

The authors present how arming Vδ2-T cells might be the basis for next-generation immunotherapies against solid tumors. Following a comprehensive overview of γδ T cell biology and innovative CAR engineering strategies, we will discuss the clinical potential of Vδ2 CAR-T cells to overcome the current limitations of immunotherapy in solid tumors.
[Clinical Cancer Research]